The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and ...

COLUMBIA, Mo. (KY3) - A new form of diagnostic imaging is changing how doctors see and treat lung conditions like cystic ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.

We are thrilled to welcome Heather to the Avalyn team and to her new role as Board Chair,” said Lyn Baranowski, chief executive officer of Avalyn. “As we look ahead, we are excited to tap into Heather ...

A doctor at the centre of a review of the treatment of more than 200 patients with lung disease is being investigated by the ...

The researchers utilized a Fra-2 transgenic mouse model that encompasses many of the features of systemic sclerosis in humans, including spontaneous systemic inflammation and fibrosis in the lungs, ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...